This website is intended for use by residents of Sweden only

About Isofol

Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.


Upcoming Events

Isofol is liquidating a subsidiary

GOTHENBURG, Sweden, December 1, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the subsidiary Isofol Medical (Incentive) AB, which has…


Stay updated on the latest news by
following Isofol on Linkedin.

LinkedIn logotype
Scroll to Top